Community/Retail

Tune in to this episode of the Independent Rx Forum for a comprehensive update on legal developments and insightful discussions on class action lawsuits and regulatory guidelines from the National Community Pharmacists Association.

Amid pharmacy strikes and ongoing challenges, technicians can identify new opportunities for growth

The biosimilars landscape is set to witness significant growth, particularly in therapeutic areas like ophthalmology and immunology, with a focus on blockbuster biologics like Humira, Stelara, and Eylea.

The cost of defending license matters and malpractice claim costs have increased over a 5-year period (2017-2022).

Pharmacists play a vital role in HIV care by addressing social determinants of health, managing complex HIV medication regimens, and providing comprehensive patient counseling.

Tarpeyo is now the first fully FDA-approved treatment for primary immunoglobulin A nephropathy, based on measures of kidney function.

Overtime, children can outgrow food allergies, like milk and eggs—however, children with private insurance are more likely to outgrow allergies than those with public insurance.

The majority (86.7%) of patients in the study got less than 7 hours of sleep each night.

Comprehensive medication reviews and drug interaction assessments are examples of clinical interventions

Tune in to this episode of Public Health Matters for a captivating exploration of global public health through the lens of a pharmacist and traveler.

These drugs have interesting mechanisms, unique use, or may support expanded indications in the future.

The pharmacies, which include 8 major chains, were revealed to provide prescription records to law enforcement agencies without court orders or warrants.

The results of the study show the importance of considering neighborhood-level disparities to address and improve medication adherence, according to investigators.

The study authors note that the findings could be significant in future HIV vaccine design and development, as well as new approaches to HIV immunotherapy.

The results found that INT301 met both its primary and secondary endpoints and could be a safe and effective option for individuals that experience food allergies.

Individuals received 4 daily short messages that reminding them to participate in self-care, active engagement, and early intervention for the first 30 days of the study.

Investigators aim to find a substitution for incomplete Freund adjuvant, which is not suitable for use in humans but shows a strong response to antigen-specific systemic immune responses.

Language gaps resulted in barriers and underdiagnosing in children with common allergies, limiting support for these patients and their families.

This approval makes birch triterpenes the first treatment for wounds associated with junctional epidermolysis bullosa to be approved by the FDA.

If approved, V116 would offer significant improvements in safety and effectiveness for the prevention of pneumococcal disease.

Previously, garadacimab was granted an orphan drug designation as a therapy for hereditary angioedema by both the FDA and EMA.

Less than 1% of individuals developed Clostridioides difficile infection (CDI), but for those who previously had a CDI the year before, 12% developed a new infection.

The antibody response among those that interrupted treatment was doubled at 4 weeks and 1.5 times greater at 26 weeks.

Treatment options can be limited for this patient population.

Rosemary Sassic-Mihalko, PharmD, is the fourth owner and first female owner of pittsburgh’s oldest pharmacy

Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, discusses the dynamic landscape of the biosimilars market, providing key insights into its current status and future projections.

Using information from clinical studies and her experiences working in the field, Stephanie Kirk describes treatment options that are on the horizon, and how removing stigma is key in HIV care.

The most recent advances included an approved vaccine that could immunize both the elderly and pregnant women, along with the release of nirsevimab.

Older individuals and individuals that experienced severe COVID-19 are at high risk of increased cardiac disturbances.

Unsuccessful arguments at trial court level are upheld on appeal